AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11409425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (t-PA) in patients without Apo E2 phenotype (190 patients)
Number of subjects: 409
Study 11409425 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with Apo E2 phenotype (31 patients)
Number of subjects: 409
Study 11409425 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E4 phenotype (111 patients, 27% of total)
Number of subjects: 409
Study 9609523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate 300 mg daily
Number of subjects: 300
Study 9609523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 7920126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral salt (sodium: potassium: magnesium 8:6:1)
Number of subjects: 100
Study 7920126 — intervention group
Group type: COMPARATOR
Intervention: Common salt
Number of subjects: 100
Study 3406540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal infusion of thrombin
Number of subjects: 0
Study 3406540 — intervention group
Group type: COMPARATOR
Intervention: Diathermy
Number of subjects: 0
Study 2021881 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Number of subjects: 60
Study 2021881 — intervention group
Group type: COMPARATOR
Intervention: As required aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Number of subjects: 60
Study 329786 — intervention group
Group type: EXPERIMENTAL
Intervention: perphenazine, 20 mg/day
Number of subjects: 54
Study 329786 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline, 125 mg/day with perphenazine, 20 mg/day
Number of subjects: 54
Study 329786 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 31601530 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with assertive community treatment (HF-ACT)
Number of subjects: 575
Study 31601530 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with intensive case management (HF-ICM) or ethnoracial-specific ICM services (HF-ER-ICM)
Number of subjects: 575
Study 31601530 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 575
Study 27699657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate 15 mg/day, sulfasalazine 1 g/day, and HCQ 400 mg/day)
Number of subjects: 72
Study 27699657 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine monotherapy (HCQ 400 mg/day)
Number of subjects: 72
Study 26366885 — intervention group
Group type: EXPERIMENTAL
Intervention: Message including the cost of a missed appointment to the health system
Number of subjects: 19959
Study 26366885 — intervention group
Group type: COMPARATOR
Intervention: Existing reminder message
Number of subjects: 19959
Study 26366885 — intervention group
Group type: EXPERIMENTAL
Intervention: General terms message expressing the cost concept
Number of subjects: 19959
Study 26366885 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving from the existing reminder to the more effective costs message
Number of subjects: 19959
Study 23406821 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation training followed by CBT (Skills/CBT)
Number of subjects: 70
Study 23406821 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling followed by CBT (Support/CBT)
Number of subjects: 70
Study 23406821 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills/CBT
Number of subjects: 70
Study 21844504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fluoropyrimidine-cisplatin
Number of subjects: 774
Study 21844504 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fluoropyrimidine-cisplatin
Number of subjects: 774
Study 19624547 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A (5 U)
Number of subjects: 14
Study 19624547 — intervention group
Group type: COMPARATOR
Intervention: Saline (isotonic saline)
Number of subjects: 14
Study 17675277 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg alpha-linolenic acid per day
Number of subjects: 9
Study 17675277 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 9
Study 15193889 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored information
Number of subjects: 1500
Study 15193889 — intervention group
Group type: EXPERIMENTAL
Intervention: General information
Number of subjects: 1500
Study 15193889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500
Study 15193889 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored information and General information
Number of subjects: 1500
Study 11642634 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 6 months (Group 1)
Number of subjects: 57
Study 11642634 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 12 months (Group 2)
Number of subjects: 57
Study 9699707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus slow-release melatonin
Number of subjects: 19
Study 9699707 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 19
Study 7986651 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized program (N = 82)
Number of subjects: 213
Study 7986651 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional program (N = 131)
Number of subjects: 213
Study 2646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol 40 mg PO tid
Number of subjects: 197
Study 2646266 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 1 mg PO tid
Number of subjects: 197
Study 2646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Megestrol and DES
Number of subjects: 197
Study 31220256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antimicrobial regimen (colistin 2×10^6 IU 4×/day, gentamicin 80 mg 4×/day, fosfomycin 3 g every 72 h)
Number of subjects: 47
Study 31220256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31220256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antimicrobial regimen
Number of subjects: 47
Study 28403619 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF+EFV
Number of subjects: 415
Study 28403619 — intervention group
Group type: COMPARATOR
Intervention: 3TC/ZDV+EFV
Number of subjects: 415
Study 26338525 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 508
Study 26338525 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 508
Study 26338525 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab in RAS and BRAF wild-type subgroup
Number of subjects: 508
Study 26338525 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab in RAS-mutation-positive subgroup
Number of subjects: 508
Study 26338525 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab in BRAF-mutation-positive subgroup
Number of subjects: 508
Study 23421731 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 0.5 mg/kg/d
Number of subjects: 57
Study 23421731 — intervention group
Group type: COMPARATOR
Intervention: Topiramate 25 mg/d increasing up to 100 mg/d
Number of subjects: 57
Study 21459374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided embryo transfer (ET)
Number of subjects: 330
Study 21459374 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal ultrasound-guided embryo transfer (ET)
Number of subjects: 330
Study 19825037 — intervention group
Group type: EXPERIMENTAL
Intervention: DentaPort ZX
Number of subjects: 831
Study 19825037 — intervention group
Group type: EXPERIMENTAL
Intervention: Raypex 5
Number of subjects: 831
Study 19825037 — intervention group
Group type: COMPARATOR
Intervention: Comparison between DentaPort ZX and Raypex 5
Number of subjects: 831
Study 19825037 — intervention group
Group type: COMPARATOR
Intervention: Comparison among same tooth type
Number of subjects: 831
Study 19825037 — intervention group
Group type: COMPARATOR
Intervention: Comparison among different tooth types in the same group
Number of subjects: 831
Study 16716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 3-6 months
Number of subjects: 0
Study 16716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for >6 months
Number of subjects: 0
Study 16716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment overall
Number of subjects: 0
Study 15477546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis extract
Number of subjects: 19
Study 15477546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11740797 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with anti-CD4 monoclonal antibodies or anticytokine agents
Number of subjects: 0
Study 11740797 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell vaccination and T-cell receptor peptide vaccination targeting autoreactive T cells
Number of subjects: 0
Study 9455619 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial-free carnitine levels in patients
Number of subjects: 11
Study 9455619 — intervention group
Group type: COMPARATOR
Intervention: Myocardial-free carnitine levels in control group
Number of subjects: 11
Study 9455619 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-free carnitine levels in patients
Number of subjects: 11
Study 9455619 — intervention group
Group type: COMPARATOR
Intervention: Plasma-free carnitine levels in control group
Number of subjects: 11
Study 7888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms day‐1 (B800)
Number of subjects: 9
Study 7888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms day‐1 (B1600)
Number of subjects: 9
Study 7888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 750 micrograms day‐1 (F750)
Number of subjects: 9
Study 7888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 1500 micrograms day‐1 (F1500)
Number of subjects: 9
Study 7888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and Fluticasone (both doses)
Number of subjects: 9
Study 7888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms day‐1 (B1600) and Fluticasone 1500 micrograms day‐1 (F1500)
Number of subjects: 9
Study 3283296 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-LA (long-acting formulation) at doses of 160, 240, and 320 mg once daily
Number of subjects: 15
Study 3283296 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol at 80 mg three times daily
Number of subjects: 15
Study 31630566 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging Mastery Program (AMP)
Number of subjects: 71
Study 31630566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 30298552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid loading (1 g sodium chloride/125 mL of water starting 2.5-h before LBNP)
Number of subjects: 9
Study 30298552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid loading
Number of subjects: 9
Study 30298552 — intervention group
Group type: COMPARATOR
Intervention: No fluid loading (control)
Number of subjects: 9
Study 26745622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy (MBT)
Number of subjects: 50
Study 26745622 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 50
Study 26745622 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 24022566 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (20g)
Number of subjects: 10
Study 24022566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22872030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (3 × 6.5 × 10⁹ CFU) for 3 months
Number of subjects: 28
Study 22872030 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 28
Study 20404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-valsartan combination (5/80 mg and then 10/160 mg)
Number of subjects: 393
Study 20404219 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine-atenolol combination (5/50 mg and then 10/100 mg)
Number of subjects: 393
Study 20404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-valsartan combination
Number of subjects: 393
Study 20404219 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine-atenolol combination
Number of subjects: 393
Study 20404219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 393
Study 19051744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia
Number of subjects: 0
Study 19051744 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 0
Study 15802904 — intervention group
Group type: EXPERIMENTAL
Intervention: omega3 fatty acid‐enhanced supplement
Number of subjects: 73
Study 15802904 — intervention group
Group type: COMPARATOR
Intervention: arginine‐enhanced supplement
Number of subjects: 73
Study 12439084 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(‐1))
Number of subjects: 14
Study 12439084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10048064 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium Yag laser radiation
Number of subjects: 18
Study 9454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical neck dissection (group A)
Number of subjects: 87
Study 9454185 — intervention group
Group type: COMPARATOR
Intervention: Non-neoplastic ORL diseases (group B)
Number of subjects: 87
Study 9454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients examined shorter than one year after operation
Number of subjects: 87
Study 9454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laryngectomy patients
Number of subjects: 87
Study 2095759 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stockings and stanozolol
Number of subjects: 68
Study 2095759 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stockings and surgical ligation of incompetent superficial veins
Number of subjects: 68
Study 2095759 — intervention group
Group type: COMPARATOR
Intervention: Elastic stockings only
Number of subjects: 68
Study 31471180 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA plus topical and intravenous CSS (Group A)
Number of subjects: 200
Study 31471180 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA plus topical CSS only (Group B)
Number of subjects: 200
Study 31471180 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA plus intravenous CSS only (Group C)
Number of subjects: 200
Study 31471180 — intervention group
Group type: COMPARATOR
Intervention: TXA only (Group D)
Number of subjects: 200
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystatin C levels before ART
Number of subjects: 0
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystatin C levels during 48 weeks of ART
Number of subjects: 0
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels with asymptomatic NCI
Number of subjects: 0
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels with mild neurocognitive disorder or HIV-associated dementia
Number of subjects: 0
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels with mild impairment
Number of subjects: 0
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels with moderate or severe impairment
Number of subjects: 0
Study 30939531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C as a diagnostic marker for NCI
Number of subjects: 0
Study 28396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound/MRI fusion guided SSPS technique
Number of subjects: 26
Study 28396863 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guided SSPS technique
Number of subjects: 26
Study 27521928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of autologous PBMCs activated by HCG (n=93)
Number of subjects: 240
Study 27521928 — intervention group
Group type: COMPARATOR
Intervention: Control group (ET without intrauterine administration) (n=105)
Number of subjects: 240
Study 24569051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amizate® (3g/day)
Number of subjects: 438
Study 24569051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amizate® (6g/day)
Number of subjects: 438
Study 24569051 — intervention group
Group type: COMPARATOR
Intervention: Chocolate drink (control)
Number of subjects: 438
Study 21836029 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan
Number of subjects: 1200
Study 20055695 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly tacrolimus ointment
Number of subjects: 349
Study 20055695 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (vehicle ointment)
Number of subjects: 349
Study 18546661 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-visual pointing responses
Number of subjects: 0
Study 18546661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointing with eyes open
Number of subjects: 0
Study 18546661 — intervention group
Group type: COMPARATOR
Intervention: Verbal azimuth estimates
Number of subjects: 0
Study 18546661 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the pointer to match egocentric target azimuth
Number of subjects: 0
Study 16457481 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian farmers
Number of subjects: 75
Study 12687657 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric analysis of covariance with homogeneous slopes
Number of subjects: 0
Study 12687657 — intervention group
Group type: EXPERIMENTAL
Intervention: t-test on difference scores
Number of subjects: 0
Study 12687657 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical approach with tests for homogeneity of regression slopes
Number of subjects: 0
Study 12687657 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric analysis of covariance with non-homogeneous slopes
Number of subjects: 0
Study 12687657 — intervention group
Group type: COMPARATOR
Intervention: Two independent samples t-test on difference scores
Number of subjects: 0
Study 10472824 — intervention group
Group type: EXPERIMENTAL
Intervention: Position of 90 degrees of flexion
Number of subjects: 25
Study 10472824 — intervention group
Group type: COMPARATOR
Intervention: Position of 45 degrees of flexion
Number of subjects: 25
Study 8744659 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE analgesia with a single subarachnoid injection of 1 mg bupivacaine plus 5 micrograms sufentanil and 25 micrograms epinephrine (total volume, 2.5 mL)
Number of subjects: 63
Study 8744659 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE analgesia
Number of subjects: 63
Study 8744659 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 63
Study 8243872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (1 mg)
Number of subjects: 11
Study 8243872 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous glucagon (0.5 mg)
Number of subjects: 11
Study 8243872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 11
Study 8243872 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous glucagon
Number of subjects: 11
Study 3549893 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response technique practiced daily for four to six weeks
Number of subjects: 0
Study 3549893 — intervention group
Group type: COMPARATOR
Intervention: Control group (quiet sitting for comparable periods without relaxation response)
Number of subjects: 0
Study 31318121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard teaching plus further tuition involving a DRE volunteer (intervention group)
Number of subjects: 48
Study 31318121 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching (control group)
Number of subjects: 48
Study 28353023 — intervention group
Group type: EXPERIMENTAL
Intervention: GUM Hydral
Number of subjects: 40
Study 28353023 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotène Oralbalance
Number of subjects: 40
Study 26853173 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI adding low-concentration desflurane (group PD)
Number of subjects: 52
Study 26853173 — intervention group
Group type: COMPARATOR
Intervention: Propofol TCI based (group P)
Number of subjects: 52
Study 26853173 — intervention group
Group type: COMPARATOR
Intervention: Both groups (group P and group PD)
Number of subjects: 52
Study 24719431 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text-message 'check-in' intervention
Number of subjects: 350
Study 24719431 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 350
Study 25951697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A and E serum concentration in CIN patients
Number of subjects: 289
Study 25951697 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-oncologic gynecologic conditions)
Number of subjects: 289
Study 22955366 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated probiotic strains (5×10⁹ cfu/strain/d for 21 days)
Number of subjects: 53
Study 22955366 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated probiotic strains (1×10⁹ cfu/strain/d for 21 days)
Number of subjects: 53
Study 19574441 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 18
Study 19574441 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC
Number of subjects: 18
Study 19574441 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 18060022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20 monoclonal antibody)
Number of subjects: 0
Study 15138160 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemically treated platelets (PCT)
Number of subjects: 645
Study 15138160 — intervention group
Group type: COMPARATOR
Intervention: Conventional platelets (control)
Number of subjects: 645
Study 12492100 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (GleevecTM)
Number of subjects: 0
Study 12492100 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha and cytarabine
Number of subjects: 0